$40.24
+0.41 (+1.03%)
Open$39.91
Previous Close$39.83
Day High$41.88
Day Low$39.81
52W High$41.88
52W Low$6.74
Volume—
Avg Volume211.1K
Market Cap645.65M
P/E Ratio—
EPS$-22.55
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-77.1% upside
Current
$40.24
$40.24
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 193.50M | 168.59M | 26.00M |
| Net Income | -360,795,724 | -282,903,076 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -357,331,610 | -295,752,770 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | — | — | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |